Dr. Sherman recently joined Nailed It: The Orthopedic Surgery Podcast to discuss early knee arthritis, high tibial osteotomy, and knee deformity. You can listen to the full episode at https://naileditortho.com/earlykneeoa/ or on iTunes.
You can watch the talk here: https://fda.yorkcast.com/webcast/Play/578ec34c004c44a89d91c9549f4998031d
Dr. Sherman’s patients who meet eligibility requirements are now able to participate voluntarily in a research study of an investigational biologic/device combination product called Novocart® 3D. This device is being tested for repair of knee cartilage defects.
Novocart® 3D is the cellular implant system that is being investigated in this clinical study. “Investigational” means that this study product has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authorities in the United States. The investigational treatment (Novocart® 3D) in this study has been used in Europe since 2003 to treat patients with damaged knee cartilage.
This use of Novocart® 3D involves two separate surgeries. In the first surgery, a small amount of knee cartilage about the size of a pencil eraser is removed from the affected knee and sent to sponsor’s manufacturing facility to be processed for re-implantation. Processing means cleaning and growing your cartilage cells in a sterile container, and then placing your own cells onto a 3-dimentional sponge-like scaffold. These cells are referred to as autologous chondrocytes (autologous = from yourself; chondrocytes = cartilage cells). During a second surgery, approximately three weeks later, the damaged area of your knee cartilage is cleaned and the sponge-like scaffold containing your autologous chondrocytes is implanted into the prepared space of the defect.
The purpose of this research study is to assess the pain, stiffness and physical function of your knee. You will receive one of two possible surgical procedures. One surgical procedure, which is the investigational procedure under study, utilizes the Novocart® 3D autologous cartilage implant system. The other possible procedure is called Microfracture and is one of the current standard of care options to treat your condition. Both surgical procedures will be followed by pain and knee function assessments and a course of physical rehabilitation.
It is possible that you will have significantly improved knee function and reduced pain as a result of these procedures compared to before the surgery. However, this cannot be guaranteed. The KOOS score is an index used to assess pain, and the IKDC score will assess physical function of your knee. Both of these scores include surveys for which you will be asked questions regarding your knee and your daily activities. Additional questionnaires will be given to you such as the SF-36 (short form general health survey), and other questions to assess the impact of your knee injury before and after the study procedures. The results of participants receiving Novocart® 3D will be compared to the results of participants undergoing the Microfracture procedure to see if one of the treatments result in better knee function and less pain.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.
“Anyone who is doing osteotomy at a relatively high volume, I implore you, please, to collect your outcomes, know your indications, follow the patients carefully [and] follow them radiographically,” he said. “Let’s get functional outcomes and return to sport outcomes, and let’s all work to collaborate to continue to push patellofemoral joint preservation well into the future.”
Tomorrow I will be participating in a ICRS Webinar Series with orthopedic specialists from Argentina, Italy and the US. Topics covered will include meniscus repair, cell-based cartilage repair, and knee osteotomy.
The event is free and open to all. You can register at http://cartilage.org/webinarseries2021.
Dr. Sherman’s article, “ACL Reconstruction 2020: A Worldwide Survey” is featured in the current issue of the ISAKOS newsletter. The article evaluates surgeons’ anterior cruciate ligament reconstruction preferences worldwide.
Click the link below to view/download the PDF. The article begins on page 36.
Dr. Sherman is honored and excited to be invited faculty at the Smith+Nephew MACKIS on Friday, November 20. His sessions will be on patellofemoral and meniscus repair.
Dr. Sherman pleased to join Wayne Gersoff, MD and Geoff Van Thiel, MD as a featured presenter at the MACI Regional Surgeon Training this Monday, September 21. His presentation topic will be “Starting Off on the Right Foot: Assessing MACI Candidates”.
Register for the virtual training at https://form.jotform.com/202153996070152.
Dr. Sherman will be a moderator of the Orthobiologics Tonight! Introductory Session this Wednesday, September 16, at 8 pm EST.
This is the first webinar presented by Biologic Association, an organization whose mission is to fostering and convene a collaboration for shared and coordinated efforts to speak with a unified voice in the musculoskeletal biologics environment, advocating for the responsible use of biologics in clinical practice, spearheading standards development, and assessing and reporting on the safety and efficacy of biologic interventions. Learn more about Biologic Association at https://www.thebiologicassociation.com.